CH and progression to myeloid malignancy in CIN. Patients with CIN (n = 185) were assessed for CH by using targeted NGS. CH was detected in 21 (11.35%;) of them. Progression to myeloid malignancy was associated with VAF >10% and mutations in SRSF2 or IDH1/2. Created with BioRender.com.